IL139169A0 - Pyrazole derivatives as p-38 map kinase inhibitors - Google Patents

Pyrazole derivatives as p-38 map kinase inhibitors

Info

Publication number
IL139169A0
IL139169A0 IL13916999A IL13916999A IL139169A0 IL 139169 A0 IL139169 A0 IL 139169A0 IL 13916999 A IL13916999 A IL 13916999A IL 13916999 A IL13916999 A IL 13916999A IL 139169 A0 IL139169 A0 IL 139169A0
Authority
IL
Israel
Prior art keywords
kinase inhibitors
map kinase
pyrazole derivatives
methods
derivatives
Prior art date
Application number
IL13916999A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL139169A0 publication Critical patent/IL139169A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13916999A 1998-05-05 1999-04-28 Pyrazole derivatives as p-38 map kinase inhibitors IL139169A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8425098P 1998-05-05 1998-05-05
US12241099P 1999-03-02 1999-03-02
PCT/EP1999/002879 WO1999057101A1 (en) 1998-05-05 1999-04-28 Pyrazole derivatives as p-38 map kinase inhibitors

Publications (1)

Publication Number Publication Date
IL139169A0 true IL139169A0 (en) 2001-11-25

Family

ID=26770756

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13916999A IL139169A0 (en) 1998-05-05 1999-04-28 Pyrazole derivatives as p-38 map kinase inhibitors

Country Status (23)

Country Link
EP (1) EP1075467B1 (xx)
JP (1) JP3590586B2 (xx)
KR (1) KR100404256B1 (xx)
CN (1) CN1147476C (xx)
AT (1) ATE292118T1 (xx)
AU (1) AU765030B2 (xx)
BR (1) BR9911013A (xx)
CA (1) CA2329065A1 (xx)
DE (1) DE69924480D1 (xx)
HK (1) HK1037374A1 (xx)
HR (1) HRP20000724A2 (xx)
HU (1) HUP0101581A3 (xx)
ID (1) ID27535A (xx)
IL (1) IL139169A0 (xx)
MA (1) MA26627A1 (xx)
NO (1) NO317985B1 (xx)
NZ (1) NZ507558A (xx)
PL (1) PL344004A1 (xx)
RU (1) RU2000130199A (xx)
TR (1) TR200003256T2 (xx)
TW (1) TW593282B (xx)
WO (1) WO1999057101A1 (xx)
YU (1) YU67600A (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
KR100609800B1 (ko) * 1998-12-16 2006-08-09 워너-램버트 캄파니 엘엘씨 Ｍｅｋ 저해제를 사용한 관절염 치료 방법
JP3989175B2 (ja) 1999-04-15 2007-10-10 ブリストル−マイヤーズ スクイブ カンパニー 環状タンパク質チロシンキナーゼ阻害剤
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6399621B1 (en) 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US6472528B1 (en) 1999-08-10 2002-10-29 Neurocrine Biosciences, Inc. Synthesis of substituted pyrazolopyrimidines
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
RU2299879C2 (ru) * 2000-01-17 2007-05-27 Байер Акциенгезелльшафт Замещенные арилкетоны
EP1259504A1 (en) 2000-03-03 2002-11-27 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
KR100840816B1 (ko) 2000-05-12 2008-06-23 젠자임 코포레이션 ＴＮＦ-α시그널링의 조절물질
JP5153047B2 (ja) 2000-08-17 2013-02-27 ギグオプティックス， インコーポレイテッド 電気光学用途用の最新ｎｌｏ物質の設計および合成
CZ20022642A3 (cs) * 2001-08-27 2003-09-17 Pfizer Products Inc. Způsob výroby dialkylpyridylboranů
KR20040029075A (ko) 2001-08-30 2004-04-03 에프. 호프만-라 로슈 아게 소염제로서의 아미노피롤 화합물
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
EP1539121A4 (en) 2002-08-29 2008-08-13 Scios Inc METHOD OF REQUESTING OSTEOGENESIS
CA2500225C (en) * 2002-09-25 2011-01-18 Ube Industries, Ltd. Pyrazole compounds
SI2298743T1 (sl) * 2003-06-26 2012-12-31 Novartis Ag Inhibitorji p38-kinaze na osnovi 5-ÄŤlenskih heterociklov
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
JP2008500991A (ja) * 2004-05-29 2008-01-17 ７ティーエム ファーマ エイ／エス 医学的使用のためのｃｒｔｈ２レセプターリガンド
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
GB0513297D0 (en) * 2005-06-29 2005-08-03 Glaxo Group Ltd Novel compounds
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2008000777A2 (en) * 2006-06-29 2008-01-03 Glaxo Group Limited Phenyl- pyrazole derivatives, process for their preparation and their pharmaceutical use
GB0621978D0 (en) * 2006-11-03 2006-12-13 Chroma Therapeutics Ltd Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
TWI464160B (zh) 2009-08-07 2014-12-11 Chugai Pharmaceutical Co Ltd Amino pyrazole derivative
JP2011201794A (ja) * 2010-03-24 2011-10-13 Fujifilm Corp ５−アミノピラゾール誘導体及びその塩の製造方法
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
CN105793245B (zh) * 2013-09-03 2018-03-20 萨勒姆有限公司 药物化合物
EP3581179A1 (en) 2013-12-27 2019-12-18 Chugai Seiyaku Kabushiki Kaisha Fgfr gatekeeper mutant gene and drug targeting same
US10479780B2 (en) 2015-06-17 2019-11-19 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
GB201612238D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
WO2018059533A1 (zh) * 2016-09-29 2018-04-05 南京明德新药研发股份有限公司 p38αMAPK激酶抑制剂及其制备方法和应用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3077499C (en) 2017-10-05 2021-09-21 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
EP3563848A1 (en) * 2018-04-30 2019-11-06 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Serpin inhibitors for the treatment of prion and prion-like diseases
GB201815699D0 (en) * 2018-09-26 2018-11-07 Mereo Biopharma 1 Ltd Synthetic method
GB201815695D0 (en) * 2018-09-26 2018-11-07 Mereo Biopharma 1 Ltd Synthetic method
JP2022506891A (ja) * 2018-11-13 2022-01-17 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712303A (en) * 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity

Also Published As

Publication number Publication date
AU4034899A (en) 1999-11-23
CN1300282A (zh) 2001-06-20
HUP0101581A2 (hu) 2002-03-28
DE69924480D1 (en) 2005-05-04
TW593282B (en) 2004-06-21
EP1075467B1 (en) 2005-03-30
AU765030B2 (en) 2003-09-04
JP2002513784A (ja) 2002-05-14
CA2329065A1 (en) 1999-11-11
MA26627A1 (fr) 2004-12-20
WO1999057101A1 (en) 1999-11-11
HRP20000724A2 (en) 2001-06-30
NO20005535D0 (no) 2000-11-02
BR9911013A (pt) 2001-02-06
TR200003256T2 (tr) 2001-04-20
RU2000130199A (ru) 2002-11-10
EP1075467A1 (en) 2001-02-14
ID27535A (id) 2001-04-12
NO317985B1 (no) 2005-01-17
JP3590586B2 (ja) 2004-11-17
HK1037374A1 (en) 2002-02-08
PL344004A1 (en) 2001-09-10
ATE292118T1 (de) 2005-04-15
HUP0101581A3 (en) 2002-07-29
CN1147476C (zh) 2004-04-28
NZ507558A (en) 2003-08-29
KR100404256B1 (ko) 2003-11-01
NO20005535L (no) 2000-11-02
KR20010043363A (ko) 2001-05-25
YU67600A (sh) 2003-07-07

Similar Documents

Publication Publication Date Title
HK1037374A1 (en) Pyrazole derivatives as p-38 map kinase inhibitors.
IL135302A0 (en) Bicyclic kinase inhibitors
MXPA02011320A (es) Derivados de pirazol triciclico como inhibidores de cinasa.
BR0014225A (pt) Derivados de pirazol
BG105481A (en) Tricyclic pyrazole derivatives
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
RS98804A (xx) N-supstituisani triciklični 3-aminopirazoli kao inhibitori pdfg receptora
ES2136037A1 (es) Inhibidores de sulfamida-metaloproteasa
ATE316083T1 (de) Adamantanderivate
AU2003228770A8 (en) Substituted pyrazolopyrimidines
DE60112330D1 (en) Pyrazolopyridinderivate
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
IL145564A0 (en) Substituted 1,4-dihydroindeno [1,2-c] pyrazoles as inhibitors of tyrosine kinase
AU2002248531A1 (en) Pyrazolopyriadine derivatives
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
ECSP992945A (es) Derivados de pirazol